Answers are grounded in this paper and cite their sources.
Narrative review reveals limited clinical readiness of pharmacogenomics in glaucoma, highlighting that early diagnosis and treatment adherence remain essential.
, though findings remain preliminary. Despite the appeal of genetically guided therapy, broader implementation in clinical practice requires larger, multicenter validation studies, functional analysis of variants, and consensus on actionable biomarkers. Until then, early diagnosis, adherence, and timely treatment remain the pillars of glaucoma care. This narrative review provides an updated overview of the current evidence, knowledge gaps, and future directions in the pharmacogenomics of glaucoma.
No takes yet. Share an insight, caveat, or question.
Labay-Tejado et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: